Fig. 3

Associations (adjusted HRs and 95% CIs) between the ADS and: a all-cause mortality, transition to HD, and the composite outcome (mortality or transition to HD); and (b) measures of poor QOL and depression symptoms. The ADS was computed for each patient, where patient responses are coded − 2 (major disadvantage) to + 2 (major advantage). A higher ADS reflects a more favorable perception of PD. PCS and MCS scores were derived from the SF-12, with lower scores indicating worse QOL, and depressive symptoms were assessed by the 10-item version of the CES-D, where CES-D ≥ 10 was a positive screen for depressive symptoms. All models adjusted for the following potential confounders: age, sex, BMI, time on PD, 13 summary comorbid conditions (Table 1), serum albumin, 24-h urine volume, and previous HD treatment. Models for: a were stratified by country and US LDO; and for (b) were additionally adjusted for country and US LDO